title: Magnetic N-succinyl chitosan/alginate beads for carbamazepine delivery.
abstract: BACKGROUND
  Epilepsy is a chronic condition characterized by recurrent unprovoked seizures. The most optimal use of drugs was limited due to their widespread systemic and central side effects. In contrast, focal drug delivery to epileptogenic focus based on superparamagnetic carrier is considered to be a promising and safe alternative. This delivery system could arrive exactly at the targeted tissue and deliver the loaded drug there with the help of an external magnetic field.
  
  
  OBJECTIVE
  A new magnetic delivery system was established to inhibit paradoxical discharge once the onset of seizures.
  
  
  METHODS
  Carbamazepine was incorporated into N-succinyl chitosan (NSC)/alginate hydrogel beads by ionic interaction. The characteristics of the beads including morphology, release behavior, and magnetic property were also investigated.
  
  
  RESULTS
  Acceptable spherical morphology, excellent slow-release property, and superparamagnetic property of the NSC/alginate hydrogel beads were observed.
  
  
  CONCLUSIONS
  The magnetic NSC/alginate beads may be acted as a sustained-release formulation. The drugs exhibit the potential magnetic property owing to Fe3O4 particles. It is promising that the released drugs are induced by the weak magnetic field of epileptogenic zone and have the potential of locating them so as to inhibit paradoxical discharge once the onset of seizures.
authors.affiliation: The Second Hospital of Lanzhou University, Lanzhou, PR China.
authors.forename: Hui-Juan
authors.initials: HJ
authors.lastname: Liu
authors.forename: Ping
authors.initials: P
authors.lastname: Li
authors.forename: Qin
authors.initials: Q
authors.lastname: Wei
mesh_terms: D000464:Alginates / Q000737:chemistry; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002220:Carbamazepine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D048271:Chitosan / Q000737:chemistry*; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D004827:Epilepsy / Q000188:drug therapy / Q000503:physiopathology; D005290:Ferric Compounds / Q000737:chemistry; D020723:Glucuronic Acid / Q000737:chemistry; D006603:Hexuronic Acids / Q000737:chemistry; D008280:Magnetics
chemical_list: D000464:Alginates; D000927:Anticonvulsants; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005290:Ferric Compounds; D006603:Hexuronic Acids; C118639:N-succinyl-chitosan; C000499:ferric oxide; D002220:Carbamazepine; D020723:Glucuronic Acid; D048271:Chitosan